Evidence map›Paper›PMID 41540456›Full record

ArticleChinese medicine2026

Thonningianin A derived from Penthorum chinense Pursh alleviates cerebral ischemia/reperfusion-mediated apoptosis and pyroptosis through the activation of PINK1/Parkin-dependent mitophagy.

Qianfang Yao, Guishan Hu, Can Yin, Anguo Wu, Guangqiang Hu, Dalian Qin, Xiaogang Zhou, Betty Yuen-Kwan Law, Xi Du, Li Chen and 5 more

Abstract read
In one paragraph

Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Qianfang Yao *Sichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, School of Pharmacy, School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, China.
Guishan Hu *Sichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, School of Pharmacy, School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, China.
Can Yin *Sichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, School of Pharmacy, School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, China.
Anguo WuSichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, School of Pharmacy, School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, China.
Guangqiang HuDepartment of Anatomy, School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, China.
Dalian QinSichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, School of Pharmacy, School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, China.
Xiaogang ZhouSichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, School of Pharmacy, School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, China.
Betty Yuen-Kwan LawState Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Taipa, Macau, China.
Xi DuDepartment of Chemistry, School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, China.
Li ChenDepartment of Neurology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China.
Jianqiao LiSichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, School of Pharmacy, School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, China.
Hong LinDepartment of Anatomy, School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, China.
Xin LongClinical Medical College, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Jianming WuSichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, School of Pharmacy, School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, China. jianmingwu@swmu.edu.cn.
Lu YuSichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, School of Pharmacy, School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, China. yulu863@swmu.edu.cn.ORCID http://orcid.org/0000-0002-8873-9138

Funding

Luzhou Science and Technology Plan Project Grant No. 2024WGR204National Natural Science Foundation of China Grant No. 81903829Sichuan Administration of Traditional Chinese Medicine Grant No. 2021MS515Sichuan Science and Technology Program 2022YFH0115Sichuan Science and Technology Program 2022YFS0620Sichuan Science and Technology Program Grant Nos. 2024YFHZ0361
6 · The paper itself

Abstract

backgroundCerebral ischemia/reperfusion injury (CI/RI) remains a critical barrier to effective ischemic stroke (IS) treatment. While mitophagy activation has been shown to attenuate apoptosis and pyroptosis, thereby ameliorating CI/RI, the therapeutic potential of natural compounds targeting this pathway remains underexplored. Penthorum chinense Pursh (PCP), a traditional hepatoprotective herb, contains Thonningianin A (TA), a bioactive compound with reported autophagic properties. However, the role and mechanisms of TA in CI/RI mitigation remain unclear.

methodsIn vivo, a middle cerebral artery occlusion/reperfusion (MCAO/R) rat model was established to evaluate TA's neuroprotective effects via TTC staining, Longa neurological scoring, and immunofluorescence staining. In vitro, oxygen-glucose deprivation/reoxygenation (OGD/R)-treated HT22 and BV2 cells were used to assess TA's impact on cell viability (MTT, Hoechst/PI staining), mitochondrial oxidative stress (DHE, TMRM, JC-1, Mito-Tracker staining and Western blot), apoptosis (flow cytometry, immunofluorescence staining, Hochest and PI staining and Western blot), and pyroptosis (EthD-2/YO-PRO-1 staining and Western blot). Autophagy and mitophagy modulation was investigated using rapamycin (Rap), 3-MA (autophagy inhibitor), CCCP (mitophagy inducer), and AC220 (mitophagy inhibitor) in EGFP-LC3-U87 and mCherry-GFP-FIS1-293T cells. Co-localization immunofluorescence and Western blotting were employed to validate PINK1/Parkin pathway involvement.

resultsTA administration significantly improved neurological function, reduced cerebral infarct volume, and attenuated neuronal damage in MCAO/R rats. In vitro, TA suppressed OGD/R-induced mitochondrial oxidative stress and apoptosis in HT22 cells while mitigating pyroptosis in BV2 microglia. Mechanistically, TA activated PINK1/Parkin-dependent mitophagy, as evidenced by enhanced LC3-II/I ratio, and increased mitochondrial-autophagosome co-localization. Crucially, TA's anti-apoptotic and anti-pyroptotic effects were abolished upon mitophagy inhibition. These findings were corroborated in the MCAO/R model, where TA upregulated PINK1/Parkin signaling and mitigated cell damage.

conclusionThis study identifies TA as a novel natural agent alleviating CI/RI by activating PINK1/Parkin-mediated mitophagy, thereby concurrently suppressing apoptosis and pyroptosis. These findings provide the first elucidating the molecular mechanis underlying TA's potential as a therapeutic candidate for IS.

Indexed as

ApoptosisAutophagyCerebral ischemia/reperfusion injuryMitophagyPenthorum chinense PurshPINK1/Parkin signaling pathwayPyroptosisThonningianin A

Identifiers

PMID41540456
PMCPMC12809999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.